160 related articles for article (PubMed ID: 9713638)
1. Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer.
Cremades MJ; Menéndez R; Pastor A; Llopis R; Aznar J
Respir Med; 1998 May; 92(5):766-71. PubMed ID: 9713638
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer].
Dabrowska M; Grubek-Jaworska H; Domagała-Kulawik J; Bartoszewicz Z; Kondracka A; Krenke R; Nejman P; Chazan R
Pol Arch Med Wewn; 2004 Jun; 111(6):659-65. PubMed ID: 15508787
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
6. How to express tumor markers in bronchoalveolar lavage.
Gómez de Terreros Caro FJ; Alvarez-Sala R; Prados MC; Callol L; Gómez de Terreros Sánchez FJ; Villamor J
Int J Biol Markers; 2004; 19(1):67-71. PubMed ID: 15077929
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer.
Li J; Chen P; Mao CM; Tang XP; Zhu LR
Asia Pac J Clin Oncol; 2014 Jun; 10(2):141-8. PubMed ID: 23551358
[TBL] [Abstract][Full Text] [Related]
9. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases.
Xu RH; Liao CZ; Luo Y; Xu WL; Li K; Chen JX; Huang YF; Chen YC; Zhu L; Yuan WB
Clin Chim Acta; 2015 Feb; 440():188-92. PubMed ID: 25304744
[TBL] [Abstract][Full Text] [Related]
10. Different cutoff values of Cyfra 21-1 for cavitary and noncavitary lung cancers.
Kim YC; Lim SC; Bom HS; Park KO; Na KJ; Park HK; Hwang JH
Lung Cancer; 2000 Dec; 30(3):187-92. PubMed ID: 11137203
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
[TBL] [Abstract][Full Text] [Related]
14. Soluble cytokeratin-19 and E-selectin biomarkers: their relevance for lung cancer detection when tested independently or in combinations.
Swellam M; Ragab HM; Abdalla NA; El-Asmar AB
Cancer Biomark; 2008; 4(1):43-54. PubMed ID: 18334733
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of CYFRA 21-1 and ProGRP in serum and bronchoalveolar lavage fluid of patients with benign lung disease].
Matsubara Y; Iwashita T; Ishimatsu Y; Shikuwa C; Kadota J; Kohno S
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):659-64. PubMed ID: 11109801
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma.
Rapellino M; Niklinski J; Pecchio F; Furman M; Baldi S; Chyczewski L; Ruffini E; Chyczewska E
Eur Respir J; 1995 Mar; 8(3):407-10. PubMed ID: 7540561
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1, a cytokeratin subunit 19 fragment, in bronchoalveolar lavage fluid from patients with interstitial lung disease.
Kanazawa H; Yoshikawa T; Yamada M; Shoji S; Fujii T; Kudoh S; Hirata K; Yoshikawa J
Clin Sci (Lond); 1998 May; 94(5):531-5. PubMed ID: 9682677
[TBL] [Abstract][Full Text] [Related]
19. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
20. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
